‘Ozempic teeth' the latest alarming side effect of weight-loss drugs: ‘Quite damaging'
As the popularity of weight-loss drugs surges, a new concern is emerging: 'Ozempic teeth.'
The term refers to a range of dental issues users have reported experiencing, such as dry mouth, bad breath, gum disease and tooth decay.
3 As the popularity of weight-loss drugs surges, a new concern is emerging: 'Ozempic teeth.'
Pixel-Shot – stock.adobe.com
These drugs suppress appetite — since eating normally stimulates saliva flow, eating less can mean less stimulation to the salivary glands, which can cause issues.
'Anecdotal reports suggest that Ozempic and similar weight loss drugs may cause dry mouth,' cosmetic dermatologist Dr. Michele Green told the Daily Mail.
'Ozempic might reduce saliva production, diminishing the mouth's natural ability to cleanse teeth.'
This can do some serious damage to your pearly whites.
'Saliva is crucial for protecting teeth, as it helps remove food particles, neutralizes acids produced by bacteria in the mouth and provides essential minerals that strengthen tooth enamel,' Green told the Daily Mail.
'When saliva levels are insufficient, the risk of cavities and tooth decay significantly increases.'
Furthermore, research shows some of the most common side effects of GLP-1s are nausea, diarrhea and vomiting — which can also pose some dental problems.
'The stomach is very acidic, and if the patients are having that acid come up into their mouth, then it really is quite damaging to the teeth,' dentist Dr Victoria Holden told The Independent.
3 'Ozempic teeth' refers to a range of dental issues users have reported experiencing, such as dry mouth, bad breath, gum disease and tooth decay.
AFP via Getty Images
One of the intended effects of GLP-1 drugs is to slow stomach emptying to promote satiety — this means food sits in the stomach for longer, which can force stomach acids up into the esophagus, resulting in acid reflux.
If you are experiencing acid reflux, Holden recommends seeing a medical expert about it 'because solving that problem from the point of view of rebuilding teeth that have been damaged by acids is complicated and expensive.'
Finally, eating less can lead to nutritional deficiencies — especially crucial vitamins like B12 and zinc — which can contribute to the discomfort, she added.
'Ozempic teeth' is only the latest in a series of conditions reportedly linked to weight loss drugs.
3 Sharon Osbourne has publicly disclosed that she uses Ozempic.
Getty Images
'Ozempic mouth' is marked by by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips and sagging skin along the lip contours and chin area.
'Ozempic face' refers to the gaunt, prematurely aged look some patients develop after shedding pounds at record speed.
And 'Ozempic butt' is the moniker attached to the saggy rear end some users are complaining about.
To help combat 'ozempic teeth,' experts suggest drinking plenty of water, making sure you get all of your necessary nutrients and practicing good dental hygiene.
It's also a good idea to tell your dentist about your medication.
'We've gone from a bit of denial in the medical field about there being a problem with that to patients now being actively encouraged to see the dentist before they start a program,' Holden told the Independent.
'And if we've got a similar thing going on with Ozempic, where potentially the outcomes can be quite damaging to the teeth and gum condition, and [if] we know about it beforehand, we can check that the patients are in optimum dental health before problems arise.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
The ‘very potent' supplement once given to Soviet cosmonauts can curb anxiety
Houston, we have a chill pill. Back in the 1960s, Soviet scientists developed a sweet little supplement that they stocked in the space kits of cosmonauts — the Russian version of an astronaut — to keep them cool under pressure. Still a popular over-the-counter option in Russia today, the drug promises to curb anxiety, cure insomnia, manage alcohol withdrawal and PTSD and promote clear thinking. Advertisement 3 Back in the 1960s, Soviet scientists developed a sweet little supplement that they stocked in the space kits of cosmonauts — the Russian version of an astronaut — to keep them cool under pressure. Gamma-Keystone via Getty Images It can even give you a bit of a high — but experts are warning that phenibut can also be a Red Scare in disguise. Utah recently classified it as a Schedule I controlled substance, placing it among the 'most dangerous drugs with no accepted medical use.' Phenibut's soothing properties come from its ability to mimic GABA — the neurotransmitter that mellows out brain activity — which makes it not dissimilar to benzodiazepines like Xanax and Valium. Advertisement Writer Delynn Willis started taking phenibut, sold under the brand names Anvifen, Fenibut and Noofen, precisely because she wanted to avoid the potentially addictive properties of benzos. A friend told her the Russian drug was dependence-free. 3 Phenibut's soothing properties come from its ability to mimic GABA — the neurotransmitter that mellows out brain activity — which makes it not dissimilar to benzodiazepines like Xanax and Valium. terovesalainen – Advertisement However, things quickly went south. 'After I had been using it for a few weeks, I started to notice I needed higher and higher doses to get the same effect,' she told Discover Magazine. When she tried to wean herself off the drug, the withdrawal symptoms were out of this world. Advertisement 'My anxiety skyrocketed, my temper shortened and I experienced dizzy spells,' she said. 'The drug has very potent psychoactive properties,' University of Michigan psychiatrist Edward Jouney told the outlet at the time. 'There's evidence it can cause addiction.' Jouney noted that it's possible that phenibut could be used as an effective treatment for anxiety under strict medical supervision. 3 While low doses — under a gram — might be safe, side effects can include vomiting, nausea, diarrhea, insomnia, depression, hallucinations, tremors and difficulty breathing. LIGHTFIELD STUDIOS – While it is technically legal in most of the US and sold online for as little as $50, buying phenibut this way is a dubious prospect. Telehealth companies aren't held to the same quality assurance standards as doctors, who can't prescribe it because it's not approved by the Food and Drug Administration for medical use. Advertisement Poison control centers have been flooded with phenibut-related calls since 2015, according to the Centers for Disease Control and Prevention, with reports describing agitation, heart irregularities, confusion — and even coma. In 2019, the FDA sent warning letters to three companies in the US for marketing phenibut as a 'dietary supplement.' Alabama took matters into its own hands and classified it as a Schedule II controlled substance in 2021, making it illegal. As of May, it is also illegal to possess, distribute or manufacture phenibut in Utah. Advertisement While low doses — under a gram — might be safe, side effects can include vomiting, nausea, diarrhea, insomnia, depression, hallucinations, tremors and difficulty breathing. It can be easy to become dependent, which can lead to death. 'The reported adverse events of phenibut are just scratching surface of a largely unregulated online drug market with no standards of quality assurance,' pharmacologists Janet Cheung and Jonathan Penm wrote in The Conversation. 'So for those students seeking the competitive edge, it looks like those extra marks are not worth it after all.'
Business Wire
3 hours ago
- Business Wire
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' Governor Glenn Youngkin, Commonwealth of Virginia, said: 'I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.' Pascal Soriot, Chief Executive Officer, AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca.
Yahoo
3 hours ago
- Yahoo
AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers
AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming years. The commitment is the largest investment to-date, according to the company in a statement Monday. It includes expansions of current sites, including in Maryland and Massachusetts, as well as new facility in Virginia. "The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of the-art centre will produce small molecules, peptides and oligonucleotides," the company said. U.K.-based AstraZeneca said it currently relies on the U.S. market for 42% of its revenues, and hopes to increase the U.S. market share to 50% with this move. Its known for oncology drugs Tagrisso and Imfinzi. AstraZeneca's leadership was scheduled to speak at an event in Washington, D.C. Monday evening, flanked by Virginia Gov. Glenn Youngkin and U.S. Commerce Dept. representatives. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030," said CEO Pascal Soriot. The strategy to invest billions in manufacturing is one being deployed by the industry in order to curry favor with President Donald Trump and his re-shoring agenda, and in hopes of avoiding strict tariffs on imported drug components manufactured abroad. Some of the largest investment commitments to-date have been Johnson & Johnson's (JNJ) $55 billion announcement and Eli Lilly's (LLY) $50 billion. With a previous $3.5 billion announced in November 2024, the new $50 billion commitment puts AstraZeneca in second. Trump has promised the pharma industry will face tariffs starting August 1. Industry leaders have pleaded with the administration for more time, and Trump has hinted the tariffs could be phased-in, as the companies work to bring their manufacturing onshore. The industry has been hoping Trump would ease up on the tariffs, in exchange for the onshoring commitments. J&J CFO Joe Wolk recently told Yahoo Finance the company has met with Trump and tried to persuade him to understand that the industry can't move facilities overnight. Meanwhile, others, like Eli Lilly CEO Dave Ricks, are hoping the administration would halt tariffs on the industry altogether. Ricks previously said that if the administration wants a commitment to make generics and other low-revenue products in exchange for no tariffs, its something the industry could consider. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
